← All trials
NCT05768854
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Jun 30, 2026
- First posted
- Mar 14, 2023
- Last posted
- Dec 18, 2023
- Enrollment
- 66
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ultragenyx Inc.Lead sponsor
- Ultragenyx Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.